Lawmakers Question Controversial Restructuring of Preventive Services Task Force

Seventeen senators have raised concerns about HHS Secretary Robert F. Kennedy Jr.'s recent overhaul of the U.S. Preventive Services Task Force, citing rushed appointment processes and lack of conflict-of-interest disclosures for new members. The senators noted that Kennedy significantly changed the task force composition by adding specialist physicians rather than maintaining its traditional focus on primary care and prevention experts, a shift they argue could introduce conflicts of interest. They also questioned whether budget cuts to the task force's parent agency may compromise its ability to conduct independent evidence reviews that guide preventive health recommendations.
The U.S. Preventive Services Task Force advises on health screening and prevention strategies that shape medical practice and insurance coverage nationwide. Kennedy's restructuring represents a fundamental departure from how the independent body has historically operated, shifting from primary care specialists who evaluate broad prevention evidence to clinical specialists whose expertise is narrowly focused on particular treatments or conditions.
The underlying infrastructure supporting the task force has deteriorated significantly. The Agency for Healthcare Research and Quality, which employs the researchers conducting evidence reviews that inform task force recommendations, has experienced severe workforce reductions over 18 months. This staffing collapse raises practical questions about whether rigorous scientific analysis—the foundation of the task force's credibility—can continue.
Changes to preventive services guidance affect millions of Americans through insurance coverage decisions, clinical guidelines, and public health priorities. If the restructured task force becomes less rigorous or more influenced by specialist interests, recommendations on screenings and preventive care could shift in ways that benefit specific medical interventions over population-level prevention. Healthcare systems, insurers, and patients relying on trusted, evidence-based guidance could face uncertainty about recommendation reliability. Conversely, stakeholders may question whether previous guidance adequately served certain medical specialties.